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Wound ﬂuid collected from chronic venous leg ulcers (chronic wound ﬂuid (CWF)) has been shown to inhibit the
growth of dermal ﬁbroblasts by interfering with cell-cycle progression from G1 into S phase. Specifically, CWF was
shown to downregulate the levels of hyperphosphorylated retinoblastoma tumor-suppressor gene (Rb) and cyclin
D1, known to be critical for entering the S phase of the cell cycle. To further elucidate the effects of CWF, a Ras-
mediated signaling pathway involving the mitogen-activated protein kinase kinase (MEK), known to modulate the
expression of these cell-cycle-regulatory proteins, was examined. Transient transfection of dermal ﬁbroblasts with
constitutively active Ras abrogated the growth suppressive effects of CWF on hyperphosphorylated Rb (ppRb) and
cyclin D1. In contrast, an MEK inhibitor PD 98059 mimicked the effects of CWF on these cell-cycle-regulatory
proteins. Concurrent treatment with PD 98059 and CWF produced additive effects. Taken together, these results
suggest that CWF inhibits the growth of dermal ﬁbroblasts at least in part by decreasing the level of active Ras,
resulting in decreased levels of ppRb and cyclin D1. Therefore, a Ras-dependent signaling pathway may mediate
the growth inhibitory effect of CWF, and reconstitution of Ras activity may overcome this growth inhibitory effect.
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Wound fluid is thought to play a critical role in the wound-
healing process (Falanga, 1992; Schultz and Mast, 1998).
Acute wound fluid has been shown to stimulate the growth
of fibroblasts and endothelial cells (Greenburg and Hunt,
1978; Jalkanen et al, 1983; Katz et al, 1991), induce chemo-
taxis (Banda et al, 1982), and increase production of extra-
cellular matrix (Jalkanen et al, 1983; Katz et al, 1991). In
contrast, wound fluid from chronic wounds (chronic wound
fluid (CWF)), has been shown to inhibit cellular proliferation
(Bucalo et al, 1993), contributing to the impaired healing of
chronic ulcers (Palolahti et al, 1993; Phillips et al, 1998).
CWF inhibits the proliferation of newborn dermal fibroblasts
(NbFb) (Bucalo et al, 1993; Mendez et al, 1999), inhibits DNA
synthesis in human neonatal fibroblasts, and arrests cells in
the G1 phase of the cell cycle (Phillips et al, 1998). Fibro-
blast proliferation is critical to the healing process (Clark,
1989; Gross et al, 1995; McClain et al, 1996), and any dis-
ruption of fibroblast proliferation can dramatically alter
proper wound healing.
The tightly regulated eukaryotic cell cycle can be broadly
divided into an S (DNA synthesis) phase and an M (mitosis)
phase, with a gap phase before S phase termed G1, and a
gap after M phase termed G2. One of the most important
regulators of G1 phase progression is the product of the
retinoblastoma tumor-suppressor gene (Rb), which modu-
lates cell-cycle progression by sequestering transcription
factors that regulate transcription of genes required for en-
try into S phase, such as E2F and histon deacetylase (Nev-
ins, 1992; Hinds and Weinberg, 1994; Weinberg, 1995).
When Rb is hyperphosphorylated (ppRb), it releases the
transcription factors, allowing passage of the cell through
G1 into the S phase (Weinberg, 1995). Rb is known to be
phosphorylated by the cyclin D1/CDK4 cyclin-dependent
kinase complex (Kato et al, 1993; Sherr, 1993; Matsushime
et al, 1994), and studies show that the cyclin D1/CDK4
complex is critical for G1 progression in mammalian cells
(Baldin et al, 1993; Sherr, 1993). The cyclin D1/CDK4 com-
plex is composed of a catalytic subunit, CDK4, and a reg-
ulatory cyclin subunit, cyclin D1 (Nasmyth, 1993). Activation
of the complex requires phosphorylation and association
with a regulatory cyclin subunit (Nasmyth, 1993). A recent
report has suggested that CWF suppresses the growth of
dermal fibroblasts by decreasing the levels of cell-cycle-
regulatory proteins, including ppRb and cyclin D1 (Seah
et al, 2001).
Ras, a 21kD guanine nucleotide-binding protein, is a key
regulator of cell growth in all eukaryotic cells (Lowy and
Willumsen, 1993). Signaling pathways from a diverse array
of extracellular stimuli converge on Ras, and Ras mediates
its effects through the activation of a cascade of protein
kinases (Campbell et al, 1998; Vojtek and Der, 1998). Ras
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functions as a molecular switch positioned at the inner
leaflet of the plasma membrane, and its activity is controlled
by a regulated guanosine diphosphate (GDP)/guanosine
triphosphate (GTP) cycle (Wittinghofer and Pai, 1991; Ma
and Karplus, 1997). The majority of Ras in quiescent cells is
in the inactive GDP-bound state, and stimulation of cells
with mitogens or serum increases the abundance of the
active GTP-bound state (Satoh et al, 1990a, b). The first
identified, and perhaps the best-characterized, downstream
effector of Ras is the protein kinase Raf that phosphorylates
a mitogen-activated protein kinase kinase (MEK) and prop-
agates the mitogen-activated protein (MAP) kinase pathway
(Macdonald et al, 1993). Active Ras binds inactive Raf and
translocates it to the plasma membrane where the Raf is
activated (Stokoe et al, 1994). Many studies have estab-
lished that cyclin D1 expression is induced by Ras (Filmus
et al, 1994; Liu et al, 1995; Arber et al, 1996; Winston et al,
1996; Aktas et al, 1997; Fan and Bertino, 1997; Kawada
et al, 1997) through a Raf/MEK/MAP kinase-dependent
pathway (Lavoie et al, 1996; Cheng et al, 1998) and the
ability of oncogenic Ras to shorten the G1 phase can be
attributed to increased induction of cyclin D1 (Liu et al,
1995; Winston et al, 1996). Furthermore, expression of
dominant-negative Ras into cycling cells causes a decline in
cyclin D1, accumulation of hypophosphorylated Rb and
subsequent growth arrest in G1, which can be overcome
with induction of cyclin D1 expression (Peeper et al, 1997).
These findings provide strong evidence that Ras-dependent
signaling plays a critical role in Rb phosphorylation, likely by
modulating the levels of cyclin D1. Although the ability to
induce Rb phosphorylation through activation of cyclin D-
dependent kinases does not account for all Ras effects on
the cell cycle, Ras control of cyclin D1 expression does
appear to be a major part of the link between Ras and the
cell-cycle machinery (Aktas et al, 1997).
CWF has been shown to inhibit the proliferation of der-
mal fibroblasts by arresting cells in the G0/G1 phase of the
cell cycle (Phillips et al, 1998). In this paper, the modulation
of ppRb and cyclin D1 by CWF through a Ras-dependent
pathway was investigated.
Results
Acute wound ﬂuid stimulated proliferation of NbFb To
compare the effects of CWF and acute wound fluid on the
proliferation of NbFb, paired cultures of NbFb were plated at
1500 cells per 35 mm culture dish. Cells were then treated
with acute wound fluid, CWF or bovine serum albumin
(BSA) at 250 mg protein per plate, and at each refeeding
fresh CWF, acute wound fluid or BSA was supplemented. At
days 3, 5, 7, and 10 after plating, total cell number per
culture dish was determined using Coulter particle Counter.
Within 7 d of treatment, acute wound fluid began to stim-
ulate the growth of NbFb, and by day 10, cells treated with
acute wound fluid displayed a significantly higher number of
cells per dish when compared with BSA-treated cells (Fig 1).
This result is consistent with previous reports that acute
wound fluid stimulated the growth of fibroblast and end-
othelial cells (Jalkanen et al, 1983; Katz et al, 1991; Green-
burg and Hunt, 1978). In contrast, CWF suppressed the
growth of NbFb (Fig 1) as previously reported (Bucalo et al,
1993; Phillips et al, 1998; Mendez et al, 1999).
CWF did not induce apoptosis To investigate whether the
CWF-induced suppression of NbFb growth may be, in part,
because of apoptosis, fluorescence-activated cell sorter
(FACS) analysis was performed on BSA- and CWF-treated
NbFb. NbFb serum starved (0.1% calf serum (CS)) for 24 h
and NbFb incubated with 0.1 mM staurosporine, known to
induce apoptosis (Tepper et al, 2000), for 6 h, were used as
controls. Apoptotic cells were quantified by FACS analysis,
using propidium iodide (PI) staining, as previously described
(Krishan, 1975; Hotz et al, 1994).
In staurosporine-treated NbFb, a large percentage of
cells were apoptotic cells as the FACS profile showed a
significant sub-G1 (hypodiploid) peak, characteristic of
apoptotic cells (Fig 2Aa). As expected, in quiescent cells
more than 75% of cells were in the G1 phase with only
11.2% of cells in S phase (Fig 2Ab). In contrast, proliferating
NbFb, stimulated with 10% CS in the presence of BSA,
had a higher percentage of cells in S phase (23.8%) (Fig
2Ac). CWF treatment caused an accumulation of cells
mostly in G1 (65.5%), and to a much lesser extent, in G2
(27%) (Fig 2Ad), as previously reported. No significant ac-
cumulation of cells in sub-G1 was, however, observed for
CWF-treated cells, suggesting that CWF does not induce
apoptosis.
To further confirm that CWF does not cause apoptosis in
NbFb, TdT-mediated dNTP Nick end labeling (TUNEL) as-
say was performed. Paired cultures of NbFb plated at
1  106 cells per 100 mm were treated with either BSA or
CWF at 250 mg protein per mL media. After 24 h of treat-
ment, cells were then processed to assess the level of flu-
orescence, indicative of apoptosis, using FACS. When the
profile of FACS analysis was overlayed between BSA- and
CWF-treated cells, the number of cells and the intensity of
fluorescence was identical between two samples (Fig 2B).
These results further confirm that CWF does not induce
apoptosis in NbFb cells.
Figure1
Effects of acute wound fluid and chronic wound fluid (CWF) on the
proliferation of newborn dermal fibroblasts (NbFb). Paired cultures
of NbFb were plated at 1500 cells per 35 mm dish. Cells were then
treated with Bovine serum albumin, acute wound fluid or CWF at 250
mg per dish. Total cell number per plate was determined using Coulter
Particle Counter on the indicated days. A representative result from
three independent experiments is shown. Acute wound fluid among the
patients was not pooled.
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Effect of CWF on the level of Ras protein Since Ras plays
a central role in mediating mitogenic activation of the cell-
cycle machinery, the effects of CWF on the level of Ras
protein were examined. Quiescent NbFb were stimulated to
proliferate with 10% CS in the presence of either CWF or
BSA. Sixteen and 20 h after serum stimulation, cells were
harvested for immunoblot analysis using specific mono-
clonal antibody against Ras. Serum stimulation did not in-
crease the level of Ras protein from that of quiescent cells
at all time points examined. Interestingly, CWF had no effect
on the level of Ras protein (Fig 3).
Effect of CWF on Ras activity To examine whether CWF
affects Ras activity, an assay based on the known
specificity of the interaction between Ras-GTP and the
Ras-binding domain (RBD) of Raf-1 (Warne et al, 1993;
Chuang et al, 1994; Hallberg et al, 1994; Pumiglia et al,
1995) was used to detect activated Ras as previously de-
scribed (Taylor and Shalloway, 1996). Quiescent NbFb were
stimulated to proliferate with 10% CS in the presence of
either CWF or BSA. At 6 and 16 h after stimulation, cells
were harvested and lysates incubated with a glutathione-S-
transferase–RBD fusion protein (GST–RBD) immobilized on
glutathione–sepharose to precipitate the active GTP-bound
form of Ras. Precipitated Ras was detected by immuno-
blotting. The level of active Ras protein in quiescent NbFb
was below detectable levels, as previously reported (Satoh
et al, 1990a, b). Serum stimulation increased the level of
active Ras at 6 and 16 h by 4-fold (Fig 4A). In CWF-treated
cells, the level of active Ras remained low at both time
points, similar to that in quiescent cells (Figs 4A and B), and
significantly lower than that in BSA-treated cells (po0.05)
(Fig 4B). These results suggest that CWF may be exerting its
effects by inhibiting Ras activity.
Constitutively active Ras abrogates effects of CWF To
further confirm that a Ras-dependent signaling pathway
mediates the effects of CWF, the constitutively active myc-
tagged (9E10) Ras38V mutant was transiently transfected
into NbFb. A set of NbFb were first synchronized into qui-
escence, then stimulated to proliferate with 10% CS for
24 h before transfection. 40 h after transfection the cells
were then treated with BSA or CWF (250 mg per mL) for
16 h. Immunoblot analyses indicate that the expression of
transfected Ras38V, as indicated by myc expression, was
Figure 2
Fluorescence-activated cell sorter (FACS) analysis profiles for
proliferating and apoptotic cells. (A) Treatment with 0.1 mM stauro-
sporine for 6 h induced apoptosis in newborn dermal fibroblasts
(NbFb), and arrows indicate the sub-G1 peaks characteristic of apo-
ptotic cells (a). FACS profiles for serum-starved NbFb (b), proliferating
NbFb (c), and chronic wound fluid (CWF)-treated NbFb (d) are shown
for comparison. (B) TUNEL assay was performed on cells treated with
BSA or CWF on subconfluent culture of NbFb.
Figure3
Chronic wound fluid (CWF) does not affect the level of Ras protein.
Paired cultures of newborn dermal fibroblasts were treated with either
bovine serum albumin or CWF in the presence of 10% calf serum (CS),
and cell lysates were subjected to immunoblot analysis. A represent-
ative blot of five independent experiments is shown. As a loading con-
trol, membrane was stained with Coomassie blue staining solution after
immunoblot analysis was completed.
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comparable between BSA- and CWF-treated cells (Fig 5A).
The levels of cyclin D1 and ppRb, which reflect the down-
stream effects of Ras activation, were examined.
In non-transfected NbFb, CWF significantly reduced the
level of cyclin D1 as compared with BSA (po0.05, Fig 5B),
as previously reported. Expression of the constitutively ac-
tive Ras38V mutant, however, abrogated the effect of CWF
on cyclin D1 (Fig 5A), and was comparable with that of BSA-
treated controls (p40.1, Fig 5B). Serum stimulation of cells
expressing constitutively active Ras38V did not cause a
further increase in cyclin D1 compared with cells expressing
only endogenous Ras (Figs 5A and B).
The levels of Rb and ppRb were analyzed in parallel,
using the same cell lysates harvested for cyclin D1 immuno-
blot analysis. In non-transfected cells, Rb shifted to ppRb in
response to serum stimulation, as expected, and this shift
was inhibited by CWF (Fig 6A). Expression of constitutively
active Ras38V blocked the effect of CWF on ppRb (Fig 6A).
CWF significantly inhibited the induction of ppRb as com-
pared with BSA control (po0.05), but in Ras38V expressing
cells, CWF did not cause any significant inhibition of the
level of ppRb (p40.1) (Fig 6B).
MEK Inhibition Mimics CWF Effects Since cyclin D1 is
regulated by a Ras-dependent signaling pathway involving
MAP kinase, the possible role of this pathway in mediating
CWF effects was examined, using PD 98059. PD 98059 is a
specific, non-competitive inhibitor of MEK activity, able to
block phosphorylation of MAP kinase by MEK without af-
fecting the activity of already phosphorylated MAP kinase.
Quiescent NbFb were pre-treated with 10 mM PD 98059 for
30 min prior to the addition of 10% CS with either CWF or
BSA (250 mg per mL) as control. Cells were then harvested
at 16 and 24 h after stimulation for immunoblot analysis.
As expected, serum stimulation caused an increase in
the level of cyclin D1 and CWF inhibited this increase (Fig
7A, lanes 1–3 and 6). Similarly, PD 98059 suppressed the
level of cyclin D1 at 16 and 24 h (Fig 7A, lanes 3, 4, 6, and 7),
indicating that MEK inhibition alone could significantly block
serum-induced increase in the level of cyclin D1 (po0.05 to
po0.01) (Fig 7B), mimicking the effect of CWF (po0.05 to
po0.01) (Fig 7B). Moreover, treatment with both CWF and
PD 98059 produced an additive effect, significantly down-
regulating the level of cyclin D1 (po0.01) (Fig 7B), even
below the level in quiescent cells (Figs 7A and B). A higher
concentration of PD 98059 completely blocked the serum-
induced increase in cyclin D1 at both 16 and 24 h (data not
shown).
Figure 4
Chronic wound fluid (CWF) suppressed the serum-induced level of
active Ras. (A) Paired cultures of newborn dermal fibroblasts were
treated with either bovine serum albumin (BSA) or CWF in the presence
of 10% calf serum (CS). Active Ras precipitated with Raf-1-Ras-binding
domain reagent was detected by immunoblot analysis. A representa-
tive blot from three independent experiments is shown. From the same
lysate, the level of total Ras was determined. As a loading control,
membrane was stained with Coomassie blue staining solution after the
immunoblot analysis was completed. (B) Immunoblot results from three
independent experiments were subjected to densitometric analysis and
values were averaged and statistical analysis was performed for each
time point to compare active Ras levels in BSA- and CWF-treated cells.
Two-way ANOVA for repeated measures, for both time and treatment
variables, showed CWF with significantly lowered active Ras levels
(a¼ 0.05, po0.001).
Figure5
Effect of chronic wound fluid (CWF) on the level of cyclin D1 in
newborn dermal fibroblasts (NbFb) expressing constitutively ac-
tive Ras38V. (A) Non-transfected and Ras38V-transfected NbFb were
treated with either bovine serum albumin (BSA) or CWF 40 h after
transfection, and harvested for immunoblot analysis 16 h after treat-
ment. A representative blot of three independent experiments is shown.
As a loading control, membranes were stained with Coomassie blue
staining solution after exposing the membrane to the X-OMAT film. (B)
Immunoblot results from three independent experiments were subject-
ed to densitometric analysis and values were averaged and statistical
analysis was performed for each time point to compare cyclin D1 levels
in BSA- and CWF-treated cells. The two-tailed, paired Student’s t test
showed a statistically significant lower level of cyclin D1 in CWF-treated
cells compared with BSA-treated cells (po0.05), but in cells expressing
constitutively active Ras38V, the effect of CWF on the level of cyclin D1
was abrogated (p40.1).
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As expected, serum stimulation caused an increase in
the level of ppRb that was inhibited by CWF at the time
points examined (Fig 8A, lanes 1–3 and 6). Similarly, PD
98059 suppressed the level of ppRb at both time points (Fig
8A, lanes 3, 4, 6, and 7). Results showed that MEK inhibition
alone significantly blocked serum-induced increase in the
level of ppRb (po0.05) (Figs 8A and B), mimicking the ef-
fects of CWF (po0.05) (Figs 8A and B). Moreover, treatment
with both CWF and PD 98059 produced an additive ef-
fect, more significantly downregulating the level of ppRb
(po0.01) at both time points (Figs 8A and B).
Discussion
CWF has been shown to specifically inhibit proliferation of
dermal fibroblasts and endothelial cells (Bucalo et al, 1993),
thus retarding the healing process, whereas acute wound
fluid was shown to stimulate proliferation of fibroblasts and
endothelial cells (Greenburg and Hunt, 1978; Jalkanen et al,
1983; Katz et al, 1991). Our results, performed in paired
cultures, confirmed the opposing effects of CWF and acute
wound fluid on the proliferation of fibroblasts. These results
further demonstrate the critical roles that the microenviron-
ment of wounds such as wound fluid may play during the
healing process. The molecular mechanisms through which
CWF exerts its inhibitory effects on the proliferation of var-
ious cell types are, however, not well understood. In this
study, we investigated the role of a Ras-dependent signa-
ling pathway in mediating the growth-inhibitory effects of
CWF.
Our results show that CWF significantly downregulated
the level of active Ras in serum stimulated NbFb. It is well
established that activation of the Ras-dependent Raf/MEK
pathway is responsible for cyclin D1 upregulation in re-
sponse to mitogenic stimulation (Filmus et al, 1994; Liu et al,
1995; Arber et al, 1996; Winston et al, 1996; Aktas et al,
1997; Fan and Bertino, 1997; Kawada et al, 1997), and the
ability to induce Rb phosphorylation through cyclin D/
CDK4-dependent kinases appears to be a major part of the
link between Ras and the cell-cycle machinery. Therefore a
Ras-dependent pathway may be the major effector path-
way mediating the effects of CWF in downregulating the
levels of ppRb and cyclin D1.
The involvement of Ras in mediating CWF effects is fur-
ther confirmed by the results of experiments expressing
constitutively active Ras38V in NbFb. The presence of con-
stitutively active Ras abrogated the CWF-induced down-
regulation of both cyclin D1 and ppRb in response to serum
stimulation. Ras activation can result in the activation of
Figure 6
Effect of chronic wound fluid (CWF) on the level of hyperphos-
phorylated Rb (ppRb) in newborn dermal fibroblasts (NbFb) ex-
pressing constitutively active Ras38V. (A) Non-transfected and
Ras38V-transfected NbFb were treated with either bovine serum albu-
min (BSA) or CWF 40 h after transfection, and harvested for immuno-
blot analysis 16 h after treatment. A representative blot of three
independent experiments is shown. (B) Immunoblot results from three
independent experiments were subjected to densitometric analysis and
values were averaged and statistical analysis was performed for each
time point to compare ppRb levels in BSA- and CWF-treated cells. The
two-tailed, paired Student’s t test showed CWF significantly inhibited
the induction of ppRb as compared with BSA control (po0.05), but in
Ras38V expressing cells, CWF did not cause any significant inhibition
of the level of ppRb (p40.1).
Figure7
Effects of chronic wound fluid (CWF) and PD 98059 and CWF on
the level of cyclin D1. (A) Newborn dermal fibroblasts were treated
with PD 98059, CWF, or a combination of both for 16 and 24 h, and
harvested for immunoblot analysis for detection of cyclin D1. A rep-
resentative blot for three independent experiments is shown. (B)
Immunoblot results from three independent experiments were subject-
ed to densitometric analysis and values were averaged and statistical
analysis was performed for each time point to compare cyclin D1 levels
among treatment groups. The two-tailed paired Student’s t test showed
that mitogen-activated protein kinase kinase inhibition alone signifi-
cantly blocked serum-induced increase in the level of cyclin D1
(po0.05–po0.01), mimicking the effect of CWF (po0.05–po0.01).
Treatment with both CWF and PD 98059 produced an additive effect,
significantly downregulating the level of cyclin D1 (po0.01), even below
the level in quiescent cells.
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multiple signaling pathways (Campbell et al, 1998; Vojtek
and Der, 1998), and the best-characterized Ras-dependent
signaling pathway involves activation of MEK (Macdonald
et al, 1993). Treatment of NbFb with the MEK inhibitor PD
98059, which specifically inhibits the Raf/MEK pathway
(Alessi et al, 1995; Dudley et al, 1995), suppressed the up-
regulation of both cyclin D1 and ppRb in response to serum
stimulation, mimicking the effects of CWF (Figs 7 and 8).
Interestingly, PD 98059, at a concentration of 10 mM,
caused a greater reduction in the level of cyclin D1 than
CWF, measured in parallel. The suppressive effect of PD
98059 on the level of ppRb was, however, less than that of
CWF. This further confirms our previous reports that the ef-
fects of CWF on ppRb involve not only cyclin D1, but also
p21Cip1/Waf1 (Seah et al, 2001). At a higher PD 98059 con-
centration (20 mM), serum induction of cyclin D1 was com-
pletely blocked (data not shown). Concomitant treatment of
NbFb with both CWF and PD 98059 produced additive ef-
fects on cyclin D1 and ppRb downregulation in response to
serum stimulation. This additive effect suggests that CWF
may be exerting its effects on cyclin D1 and ppRb primarily
through a Raf/MEK, Ras-dependent pathway. It would be
interesting to determine whether this pathway can be com-
pletely blocked using higher concentrations of CWF. More-
over, it has been previously reported that the extent of
growth inhibition by CWF varies among patients (Phillips
et al, 1998). It may be that CWF from ulcers of longer du-
ration may be more potent in suppressing Ras activity, thus
almost completely inhibiting the important pathway required
to induce Rb phosphorylation.
Results presented here suggest that CWF exerts it ef-
fects on cell-cycle-regulatory proteins, in part, by down-
regulating active Ras. The mechanism through which CWF
is able to downregulate the level of active Ras still remains
to be investigated. It is possible that factors in CWF com-
pete with growth factors for receptor binding sites, resulting
in decreased receptor tyrosine kinase activation of Ras. Al-
ternatively, factor(s) in CWF may upregulate molecules that
interfere with the GTP-loading action of Ras, resulting in
reduced levels of active Ras. The possibility that factor(s) in
CWF interfere with MEK phosphorylation resulting in dimin-
ished MAP kinase pathway activation also cannot be ruled
out.
Experiments described in this report were performed
using NbFb. Presumably, fibroblasts exposed to CWF
in vivo would be adult dermal fibroblasts, and it is not clear
whether CWF would have a similar effect on adult dermal
fibroblasts. When CWF was added to primary human der-
mal fibroblasts cultured from biopsies taken from normal
adult skin, ages ranging from 40 to 70 y, CWF similarly
suppressed the proliferation of these adult fibroblasts (Park
et al, 1998). These results suggest that effects of CWF on
adult dermal fibroblasts would be similar to those on NbFb.
It is yet to be determined what factor(s) in CWF is re-
sponsible for the growth inhibitory activity. Our previous
studies demonstrated that CWF inhibits growth of NbFb in
a concentration-dependent fashion (Phillips et al, 1998).
When 100, 250, 500, and 1000 mg protein of CWF was
added to paired cultures of NbFb, 500 mg protein per plate
showed about 60%–75% inhibition whereas 1000 mg pro-
tein per plate inhibited the growth of NbFb by greater than
90% (Phillips et al, 1998). Preliminary biochemical analysis
using column chromatograph fractionations suggested that
the growth inhibitory activity was highest in fractions that
contain molecules with molecular weights less than 30 kDa
(Bucalo et al, 1993). Among them, tumor necrosis factor-a
(TNF-a) and transforming growth factor-b (TGF-b) were the
best suggested candidates that may inhibit proliferation of
NbFb. Neutralizing TNF-a activity in CWF with a specific
monoclonal antibody against TNF-a did, however, not re-
duce growth inhibitory activity in CWF (Mendez et al, 1999).
TGF-b, when added alone to the dermal NbFb, suppressed
proliferation of these cells (Mendez et al, 1999) but neutral-
izing its activity in CWF using a specific monoclonal anti-
body did not reduce the growth inhibitory activity (Mendez
et al, 1999). These results suggest that neither TNF-a nor
TNF-b present in CWF play a role in suppressing the growth
of dermal NbFb.
CWF was reported to contain an excess level of pro-
teases (Wysocki and Grinnell, 1990), resulting in excess
degradation of fibronectins (Wysocki and Grinnell, 1990).
MMP-2 and MMP-9 were at least 5-fold higher in CWF
when compared with acute wound fluid (Wysocki et al,
1993). Furthermore, TIMP-1 is reduced in CWF (Howard
et al, 1994). Pro-inflammatory cytokine levels such as TNF-a
and interleukin (IL)-1b were about 100-fold higher in CWF
than in mastectomy fluid (Mast and Schultz, 1996), whereas
Figure 8
Effects of chronic wound fluid (CWF) and PD 98059 on the level of
newborn dermal fibroblasts (ppRb). (A) Newborn dermal fibroblasts
were treated with PD 98059 (10 mM), CWF (125 mg per mL), or a com-
bination of both for 16 and 24 h, and harvested for immunoblot analysis
for detection of retinoblastoma tumor-suppressor gene (Rb). A repre-
sentative blot for three independent experiments is shown. (B) Immuno-
blot results from three independent experiments were subjected to
densitometric analysis and values were averaged and statistical anal-
ysis was performed for each time point to compare ppRb levels among
treatment groups. The two-tailed paired Student’s t test showed that
mitogen-activated protein kinase kinase inhibition alone significantly
blocked serum-induced increase in the level of ppRb (po0.05), mim-
icking the effect of CWF (po0.05). Treatment with both CWF and PD
98059 produced an additive effect, more significantly downregulating
the level of ppRb (po0.01) at both time points.
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the levels of IL-8 were similar in CWF and acute wound fluid
(Mast and Schultz, 1996). How the changes in the overall
level of cytokines effect impaired healing are, however, yet
to be elucidated.
Our results show that CWF affects a definable pathway
leading to inhibition of cellular proliferation, even in the
presence of serum stimulation. It is therefore unlikely that a
lack of mitogenic growth factors is responsible for the in-
hibitory effect of CWF. This is consistent with a previous
study showing no significant differences in the levels of
growth factors or cytokines between healing and non-heal-
ing chronic venous ulcers (Harris et al, 1995). Moreover,
clinical studies involving the external application of growth
factors to chronic venous ulcers have failed to show con-
sistent efficiency. The presence of specific growth inhibitory
factor(s) may be responsible for the inconsistent clinical
outcomes with novel treatment modalities such as growth
factor therapy and skin equivalent allografts. Since most
known growth factors stimulate mitogenesis through a Ras-
dependent Raf/MEK pathway, the use of growth factor
therapy and living skin equivalents to deliver mitogenic
growth factors to enhance wound cell proliferation is des-
tined for poor outcomes. Perhaps use of pharmacologic
substances that activate alternative mitogenic pathways
would offer better treatment options. Understanding the
underlying molecular mechanisms responsible for the im-
paired healing seen in chronic wounds would greatly
enhance development of more effective therapies. The
findings reported here expand on studies that have dem-
onstrated the ability of CWF to inhibit dermal fibroblast
proliferation, and further elucidate the molecular mecha-
nisms through which CWF is able to exert its growth
inhibitory effects. These results may, in the future, allow
development of more effective therapies for the treatment of
chronic wounds.
Materials and Methods
Fibroblast isolation and culture NbFb were cultured as previ-
ously described (Gilchrest, 1980). Briefly, newborn foreskins were
treated for 5 min in a povidine–iodine bath, followed by a 5 min
70% ethanol bath. Biopsies were then placed in a 1 mg per mL
trypsin solution overnight at 41C to dissociate the dermis from the
epidermis and adipose tissues. Isolated dermal tissue was then cut
into 1–2 mm fragments and placed in etched plastic culture plates.
Fibroblasts were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% bovine CS, devoid of any antibiotic or anti-
mycotic agents. Second or third passage cells were used in all the
experiments.
Collection of chronic and acute wound ﬂuids CWF and acute
wound fluid from each patient was collected and processed sep-
arately and was not combined for any experiments. To collect CWF,
patients with documented chronic venous ulcers, recruited with the
approval of the Institutional Review Board at Boston Medical Cen-
ter, were treated with Allevyn foam dressings (Smith & Nephew, La
Jolla, California) for 24–48 h. Patients with infected ulcers or ma-
lignancies were excluded. CWF was then extracted from the foam
dressings through sterile syringes with 20-gauge stainless-steel
needles. The collected CWF was immediately diluted (1:10) with
DMEM containing the protease inhibitors Aprotinin (2 mg per mL)
and phenylmethylsulfonyl fluoride (10 mg per mL). Large debris was
removed by centrifugation at 14,000  g for 15 min. The CWF was
then stored at 701C until use. Just prior to addition to cell cul-
tures, the CWF was filtered through a 0.4 mm syringe filter to re-
move bacteria. Subsequently, protein concentration expressed in
mg per mL was determined. In order to avoid possible contamina-
tion of CWF among the patients each Allevyn foam dressing was
processed separately. Then, CWF collected from each patient was
used independently in each experiment. To collect acute wound
fluid, gauze dressings were placed immediately after a Moh’s sur-
gery for 10–30 min. The gauze dressings were then removed and
the acute wound fluid was extracted and processed employing the
same procedures used for CWF as described above. The study
was conducted according to the Declaration of Helsinki Principles
and the Institutional Review Board at Boston Medical Center ap-
proved the studies. Informed consent signatures were excused by
the committee because otherwise discarded wound dressings
were used.
Cell synchronization NbFb were plated at 100,000 cells per
60 mm dish in DMEM containing 10% CS and allowed to settle
overnight. Cells were then serum starved in DMEM with 0.1% CS
for 72 h to synchronize them into G0. Seventy-two hours serum
starvation of NbFb has previously been shown to induce quies-
cence in at least 90% of the cells (Yaar et al, 1990).
Transient transfections Escherichia coli bacteria containing
myc-tagged (9E10) Ras38V cDNA were obtained from Dr Alan
Hall (London, UK). Quiescent NbFb plated at 1  106 cells per 100
mm dish were stimulated to initiate DNA synthesis with 10% CS.
After 24 h stimulation, Ras38V cDNA was transiently transfected
into NbFb using Lipofectamine Plus reagents (Gibco BRL Life
Technologies, Carlsbad, California) according to manufacturer’s
instructions. Forty hours after transfection, cells were treated with
either BSA or CWF (250 mg per mL) for 6–16 h. Maximal expression
for transfected Ras38V occurred between 48 and 72 h after
transfection (data not shown). Non-transfected NbFb expressing
only endogenous Ras, treated with either BSA or CWF (250 mg per
mL), were used as control.
MEK inhibition with PD 98059 NbFb plated at 1  105 cells per
60 mm culture dish were synchronized into G0 by serum-starvation
a described above. Paired cultures were pre-treated for 30 min
with 10 mM of the MEK inhibitor PD 98059 (Calbiochem, LaJolla,
California) or an equal volume of vehicle alone. PD 98059 [2-
(20amino-30-methoxyphenyl)-oxanapthalen-4-one] is a highly spe-
cific, non-competitive, inhibitor of MEK activity and consequently,
it blocks the MAP kinase pathway (Alessi et al, 1995; Dudley et al,
1995). Furthermore, growth inhibitory effects of PD 98059 are rap-
idly reversed when the compound is removed from culture media
(Alessi et al, 1995; Dudley et al, 1995). After 30 min pre-treatment,
CWF or BSA (250 mg per mL) was added to NbFb in the presence
of 10% CS for 16–24 h. Cells were then harvested for immunoblot
analysis.
Ras activity assay Quiescent NbFb were treated with either 250
mg per mL CWF or BSA in the presence of 10% CS for 6–16 h and
harvested by scraping in a Mg2þ lysis buffer (125 mM HEPES,
750 mM NaCl, 5% Igepal CA-630, 50 mM MgCl2, 5 mM EDTA,
10% glycerol). After protein concentration was determined (Biorad
Detergent Compatible Protein Assay, Bio-Rad, Hercules, Califor-
nia), cell lysates were then incubated with a GST–RBD immobilized
on glutathione–sepharose (Upstate Biotechnology, Charlottesville,
Virginia) for 30 min at 41C with rocking. Approximately 15 mL of
packed GST–RBD beads were used per 15–30 mg of cell lysate
protein. After the 30 min incubation, beads were washed in Mg2þ
lysis buffer. Precipitated protein was released from the beads by
boiling the samples in Laemmli sample buffer (Laemmli, 1970). The
samples were then subjected to 12% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) (Laemmli, 1970) and precipitated ac-
tive Ras was detected by immunoblotting. Raf-RBD has a signif-
icantly lower affinity for inactive Ras-GDP than for active Ras-GTP,
and so only active Ras-GTP is detected under the conditions of
this assay (Taylor and Shalloway, 1996).
472 SEAH ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Protein extraction and immunoblot analysis NbFb were har-
vested in a RIPA lysis buffer (0.25 M Tris/HCl, 0.75 M NaCl, 2.5%
SDS, 0.1% Triton) containing phenylmethylsulfonyl fluoride (1 mM),
aprotinin (1 mM), and okadaic acid (1 mM) at 16, 20, 24, and 28 h
after treatment. Lysate samples were sonicated briefly and cen-
trifuged at 13,000g to remove the particulate fraction. Lysate sam-
ples was resolved by SDS-PAGE on 5%–12% polyacrylamide gels
and transferred onto PVDF membranes (Bio-Rad). The membranes
were blocked in 5% non-fat milk and blotted with antibody against
Rb (Pharmingen, San Diego, California), cyclin D1 (Pharmingen),
and Ras (Tranduction Labs, Lexington, Kentucky). This was fol-
lowed by incubation with the appropriate secondary antibodies
conjugated to horseradish peroxidase. Protein bands were visu-
alized using ECL detection system (Amersham, Piscataway, New
Jersey).
FACS analysis Flow cytometry was used to determine whether
CWF induces apoptosis in NbFb. Cells were plated at 1  106 cells
per 100 mm dish, and synchronized into G0 as described above.
Cells were then treated with either BSA or CWF (250 mg per mL) for
24 h in the presence of 10% CS. For positive apoptosis controls,
NbFb were incubated with 0.1 mM staurosporine (Calbiochem), a
potent protein kinase inhibitor capable of inducing a strong apo-
ptotic response in normal human fibroblasts (Tepper et al, 2000).
Parallel cultures of NbFb were serum starved in DMEM with 0.1%
CS for 24 h as an additional control. Single color flow cytometric
analysis of DNA content by PI staining was carried out. After the
various treatments, cells were detached with 1 mg per mL trypsin/1
mM EDTA, pelleted, washed, and fixed in 70% ethanol. Fixed cells
were washed again with ice-cold phosphate-buffered saline (PBS)
before incubation in 8 mg per mL RNAse A (Sigma, St Louis, Mis-
souri) and 18 mg per mL PI (Sigma) at 371C for 30 min. Cells were
analyzed with a FACScan (Becton Dickinson, Sparks, Maryland).
Cell-cycle analysis of ungated data and determination of the per-
centage of cells in G0/G1, S, and G2/M were calculated using
CELLQuest software.
TUNEL apoptosis assay Paired cultures of NbFb were plated at
1  106 cells per 100 mm dish and 24 h after plating, cells were
treated with BSA or CWF (250 mg protein per mL media). Twenty to
24 h after the treatments, cells were trypsinized, and then fixed in
2% paraformaldehyde in PBS (pH¼ 7.4) for 15–20 min at room
temperature. Cell membranes were then permeabilized by treating
the cells with 0.1% Triton X-100 in 0.1 sodium citrate. Cells were
then further processed using In Situ Cell Death Detection Kit, Flu-
orescein (Roche Applied Science, Mannheim, Germany) according
to the manufacturer’s protocol. The level of fluorescence in each
treatment group was determined using FACS analysis.
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